Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA 06-May-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA Geneva, Switzerland, May 6, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today gives notice of the Annual General Meeting ("AGM") of shareholders to be held on May 31, 2022.

Due to the ongoing COVID-19 pandemic, the Board of Directors decided that the meeting will be held without the presence of shareholders in accordance with the requirements of article 27 of Ordinance 3 issued by the Swiss Federal Council on Measures to Combat the Coronavirus. Guidelines on how to deliver voting instructions can be found in the AGM formal invitation, which will be sent out on Monday, May 9, 2022 to registered shareholders.

Agenda and Proposals of the Board of Directors:

1. Approval of the Annual Report, Statutory Financial Statements and Consolidated Financial Statements for the year 2021

The Board of Directors recommends that the General Meeting approves the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for the year 2021.

2. Appropriation of Results

The Board of Directors proposes to carry forward the loss for the year 2021 of CHF 29'553'450, thereby bringing the loss carried forward from CHF 157'935'435 to CHF 187'488'885.

3. Discharge of the Board of Directors and the Executive Committee

The Board of Directors proposes that the General Meeting grants discharge to each and all members of the Board of Directors, still active or having resigned, and of the Executive Committee for their activities in the financial year 2021.